Steven James

Steven P. James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is Chief Executive Officer and Director of Pionyr Immunotherapeutics. Previously, he was President and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was President and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. He serves as a trustee of Middlebridge School in Rhode Island. Mr. James is currently Chairman of Antiva Biosciences and Director of Allakos Inc and Ventus Therapeutics. He was formerly a Director of Ocera Inc. (acquired by Mallinckrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).